Hims & Hers partners with Lilly to expand access to obesity medicines
Bitget2026/11/06 11:47- Hims & Hers entered an agreement with Eli Lilly to expand access to FDA-approved obesity medicines Zepbound and Foundayo through its platform.
- Eligible patients prescribed treatment can receive home delivery without leaving the platform, at the same self-pay prices available to other patients.
- Monthly self-pay pricing starts at $149 for Foundayo and $299 for Zepbound.
- The platform committed not to offer compounded copies of Lilly’s GLP-1 medicines, while both companies pledged to protect independent prescribing decisions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cybertruck orders far exceed pre-production capacity, Tesla (TSLA.US) to refund deposits to a large number of customers
Elon Musk stated that Tesla will refund the Cybertruck deposits to a significant number of customers.
Barrick Gold (B.US) Q3 Results Mixed: Benefiting from Gold Price Dividend While Facing Cost Pressures
Barrick Mining (B.US) will release its financial results for the third quarter of 2026 before the U.S. stock market opens on November 9.
Europe Becomes a Safe Haven Amid AI Turbulence! Citi Turns Bullish on European Stocks, Downgrades US Stocks: Low AI Exposure Seen as Key Advantage
Citigroup strategists have downgraded the rating of U.S. stocks and upgraded the rating of European stocks, following the recent market turbulence caused by upheaval in the artificial intelligence industry.
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Crypto prices
More
